<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg"/></p>
<p>強生預計 2025 年第四季度及 2026 年將出現收益稀釋。圖片來源：Skorzewiak/Shutterstock.com。</p>
<p>強生（J&amp;J）已完成對 Halda Therapeutics 的收購，這是一家臨牀階段的生物技術公司，收購金額為 30.5 億美元現金。</p>
<p>此舉將 Halda 的調控誘導鄰近靶向嵌合體（RIPTAC）平台納入強生的腫瘤學產品組合，支持針對包括前列腺癌在內的多種實體腫瘤的口服靶向療法的開發。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - JNJ-6358 在肺腺癌中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM：4D Pharma Plc 的 MRx-518</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>此次收購包括 HLD-0915，這是一種臨牀階段的每日一次口服前列腺癌療法。該療法利用 RIPTAC 平台精確靶向癌細胞，旨在解決耐藥機制。</p>
<p>此外，該交易還為強生的產品管線增加了早期階段的乳腺癌、肺癌及其他腫瘤類型的候選藥物，均採用 RIPTAC 技術。</p>
<p>公司表示，該平台可能使得開發腫瘤學以外的其他靶向療法成為可能。</p>
<p>隨着交易在 2025 年完成，強生預計 2025 年第四季度及 2026 年將出現收益稀釋。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>對調整後每股收益的總影響預計約為 0.20 美元，平均分配在 2025 年和 2026 年，反映與 Halda 員工股權、融資和整合成本相關的費用。</p>
<p>強生創新藥物全球主席兼執行副總裁 Jennifer Taubert 表示：“這一戰略里程碑強調了我們通過突破性科學和變革性藥物重新定義癌症治療的承諾。</p>
<p>“我們很高興正式歡迎才華橫溢的 Halda 團隊加入強生，並期待共同努力實現消除癌症的共同目標。”</p>
<p>強生創新藥物研發執行副總裁 John Reed 表示：“現在我們已完成此次收購，我們將專注於推進這一有前景的創新產品候選藥物管線的潛力，並利用強大的 RIPTAC 平台發現更多腫瘤學及其他領域的分子。”</p>
<p>2025 年 11 月，強生 簽署了最終協議 收購 Halda。</p>
<h2>製藥技術卓越獎 - 提名已關閉</h2>
<p>提名現已關閉，感謝所有參與的組織——你們的響應非常出色，展示了卓越的創新、領導力和影響力。</p>
<p><strong>行動中的卓越</strong></p>
<p>因在 綜合製造 方面的業務擴展而獲得 2025 年製藥技術卓越獎的 Upperton Pharma Solutions 正在迅速擴大其在英國的 GMP 和無菌製造足跡。瞭解 Upperton 的綜合 CDMO 模型如何幫助製藥公司從早期開發轉向臨牀和小眾商業供應，減少交接和加快時間表。</p>
<p>發現影響</p>

強生

<p>強生（Johnson & Johnson，J&J）以 30.5 億美元現金收購 Halda Therapeutics，增強其腫瘤學產品組合，特別是 Halda 的調控誘導接近靶向嵌合體（RIPTAC）平台。此次收購包括 HLD-0915，一種用於前列腺癌的口服療法，以及其他腫瘤的早期候選藥物。J&J 預計由於整合成本，2025 年和 2026 年的每股收益將稀釋約 0.20 美元。J&J 的高管強調此次收購在推進癌症治療和開發新療法方面的戰略重要性</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg"/></p>
<p>J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026. Credit: Skorzewiak/Shutterstock.com.</p>
<div class="lb-trans"><p>強生預計 2025 年第四季度及 2026 年將出現收益稀釋。圖片來源：Skorzewiak/Shutterstock.com。</p>
</div><p>Johnson &amp; Johnson (J&amp;J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.</p>
<div class="lb-trans"><p>強生（J&amp;J）已完成對 Halda Therapeutics 的收購，這是一家臨牀階段的生物技術公司，收購金額為 30.5 億美元現金。</p>
</div><p>This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to J&amp;J’s oncology portfolio, supporting the development of oral, targeted therapies for several solid tumours, including prostate cancer.</p>
<div class="lb-trans"><p>此舉將 Halda 的調控誘導鄰近靶向嵌合體（RIPTAC）平台納入強生的腫瘤學產品組合，支持針對包括前列腺癌在內的多種實體腫瘤的口服靶向療法的開發。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - JNJ-6358 in Lung Adenocarcinoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - JNJ-6358 在肺腺癌中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: 4D Pharma Plc's MRx-518</h4>
<div class="lb-trans"><h4>NPVM：4D Pharma Plc 的 MRx-518</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The acquisition includes HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer. This therapy utilises the RIPTAC platform for precision targeting of cancer cells, aiming to address resistance mechanisms.</p>
<div class="lb-trans"><p>此次收購包括 HLD-0915，這是一種臨牀階段的每日一次口服前列腺癌療法。該療法利用 RIPTAC 平台精確靶向癌細胞，旨在解決耐藥機制。</p>
</div><p>Additionally, the deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&amp;J’s pipeline.</p>
<div class="lb-trans"><p>此外，該交易還為強生的產品管線增加了早期階段的乳腺癌、肺癌及其他腫瘤類型的候選藥物，均採用 RIPTAC 技術。</p>
</div><p>The company indicated that this platform could potentially enable the development of additional targeted therapies beyond oncology.</p>
<div class="lb-trans"><p>公司表示，該平台可能使得開發腫瘤學以外的其他靶向療法成為可能。</p>
</div><p>With the deal closing in 2025, J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026.</p>
<div class="lb-trans"><p>隨着交易在 2025 年完成，強生預計 2025 年第四季度及 2026 年將出現收益稀釋。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>The total impact on adjusted earnings per share is expected to be around $0.20, divided equally between 2025 and 2026, reflecting charges related to Halda employee equity, financing, and integration costs.</p>
<div class="lb-trans"><p>對調整後每股收益的總影響預計約為 0.20 美元，平均分配在 2025 年和 2026 年，反映與 Halda 員工股權、融資和整合成本相關的費用。</p>
</div><p>J&amp;J innovative medicine worldwide chairman and executive vice president Jennifer Taubert said: “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines.</p>
<div class="lb-trans"><p>強生創新藥物全球主席兼執行副總裁 Jennifer Taubert 表示：“這一戰略里程碑強調了我們通過突破性科學和變革性藥物重新定義癌症治療的承諾。</p>
</div><p>“We are excited to formally welcome the talented Halda team to J&amp;J and look forward to working together to achieve our shared goal of eliminating cancer.”</p>
<div class="lb-trans"><p>“我們很高興正式歡迎才華橫溢的 Halda 團隊加入強生，並期待共同努力實現消除癌症的共同目標。”</p>
</div><p>J&amp;J innovative medicine R&amp;D executive vice-president John Reed said: “Now that we have finalised this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”</p>
<div class="lb-trans"><p>強生創新藥物研發執行副總裁 John Reed 表示：“現在我們已完成此次收購，我們將專注於推進這一有前景的創新產品候選藥物管線的潛力，並利用強大的 RIPTAC 平台發現更多腫瘤學及其他領域的分子。”</p>
</div><p>In November 2025, J&amp;J signed a definitive agreement for the acquisition of Halda.</p>
<div class="lb-trans"><p>2025 年 11 月，強生 簽署了最終協議 收購 Halda。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 提名已關閉</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名現已關閉，感謝所有參與的組織——你們的響應非常出色，展示了卓越的創新、領導力和影響力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行動中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>因在 綜合製造 方面的業務擴展而獲得 2025 年製藥技術卓越獎的 Upperton Pharma Solutions 正在迅速擴大其在英國的 GMP 和無菌製造足跡。瞭解 Upperton 的綜合 CDMO 模型如何幫助製藥公司從早期開發轉向臨牀和小眾商業供應，減少交接和加快時間表。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>發現影響</p>
</div>

強生以 30.5 億美元收購 Halda Therapeutics